- Home
- NGD vs MIRM Comparison
NGD vs MIRM Comparison
Compare NGD & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGD
- MIRM
- Stock Information
- Founded
- NGD N/A
- MIRM 2018
- Country
- NGD Canada
- MIRM United States
- Employees
- NGD N/A
- MIRM N/A
- Industry
- NGD
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- NGD
- MIRM Health Care
- Exchange
- NGD Nasdaq
- MIRM Nasdaq
- Market Cap
- NGD 3.9B
- MIRM 3.3B
- IPO Year
- NGD 2004
- MIRM 2019
- Fundamental
- Price
- NGD $6.27
- MIRM $76.19
- Analyst Decision
- NGD Buy
- MIRM Strong Buy
- Analyst Count
- NGD 2
- MIRM 9
- Target Price
- NGD $5.50
- MIRM $73.89
- AVG Volume (30 Days)
- NGD 12.9M
- MIRM 994.4K
- Earning Date
- NGD 10-28-2025
- MIRM 08-06-2025
- Dividend Yield
- NGD N/A
- MIRM N/A
- EPS Growth
- NGD N/A
- MIRM N/A
- EPS
- NGD 0.18
- MIRM N/A
- Revenue
- NGD $1,031,700,000.00
- MIRM $429,161,000.00
- Revenue This Year
- NGD $51.33
- MIRM $52.71
- Revenue Next Year
- NGD $47.75
- MIRM $19.71
- P/E Ratio
- NGD $33.65
- MIRM N/A
- Revenue Growth
- NGD 27.25
- MIRM 62.33
- 52 Week Low
- NGD $2.31
- MIRM $36.86
- 52 Week High
- NGD $6.29
- MIRM $76.02
- Technical
- Relative Strength Index (RSI)
- NGD 85.16
- MIRM 77.87
- Support Level
- NGD $6.00
- MIRM $73.12
- Resistance Level
- NGD $6.29
- MIRM $76.02
- Average True Range (ATR)
- NGD 0.18
- MIRM 2.38
- MACD
- NGD 0.07
- MIRM 0.04
- Stochastic Oscillator
- NGD 97.26
- MIRM 97.73
About NGD New Gold Inc.
New Gold Inc participates in the development and operation of intermediate mining properties. The company has a portfolio of two primary assets which are also its operating segments: the Rainy River Mine and the New Afton Mine in Canada. The company also owns the Cerro San Pedro Mine in Mexico. The company derives revenue from the sale of gold, copper, and silver.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.